Will Biogen use its cash hoard to pay a dividend?; Ardea raising $144M;

@FierceBiotech: Check out FierceBiotech's FDA Approvals of 2011 Slideshow. Report | Follow @FierceBiotech

@JohnCFierce: Biogen CFO mulls dividend--eventually. My bet is they want to use their $3B in cash for deals. More | Follow @JohnCFierce

@FierceMedDev: Device Makers Said to Double FDA Fees to Produce Faster Reviews--Bloomberg. Article | Follow @FierceMedDev

@MarkHFierce: How to better detect genes linked to cancer? A liquid laser, it seems. If it is safe for the patient, then why not? Story | Follow @MarkHFierce

> Biogen Idec CFO Paul Clancy grabbed a headline with his thoughts on the possibility of paying a dividend with some of the $3.1 billion cash on hand. Biogen ($BIIB) has to balance demands for the cash, from new deals, to buybacks and a possible dividend. "We always get this question as either/or," Clancy tells Bloomberg. "The reality is it's a mixture of all, potentially." Story

> Shares of Ardea Biosciences ($RDEA) slipped this morning when it priced an offering designed to raise $144 million to back a late-stage drug study. Release

> In an update, AcelRx Pharmaceuticals ($ACRX) says that the two remaining items required by the FDA prior to the initiation of the Phase III study for ARX-01 are "progressing." Release

@FiercePharma: Vertex to offer co-pay assistance, case managers to help Kalydeco patients cover the $294K cost--WSJ. News | Follow @FiercePharma

> Pfizer pulls mixed-up contraceptive pills. News

> What will Dendreon's new chief do about Provenge? More

> FDA finds puppies and moths not guilty of DTC interference. Story

Drug Delivery News

> Impax licenses U.S. rights to three versions of AstraZeneca migraine drug. News

> AMT's Glybera, delivered through virus, faces Euro reg delay. More

> Takeda abandons Euro rights to Durect's controlled-release pain drug. Story

> New drug delivery system slows water filtration, displaces air. Article

> Amylin gets FDA OK for weekly diabetes drug Bydureon. News

> Nanotech transforms cyclosporine into safer transplant drug. Item

Medical Device News

> ConforMis nails $89M for iTotal knee manufacturing + launch. Article

> Roche will nominate Illumina board candidates. Item

> CartiHeal scores $5M ahead of 2013 product launch. Story

Biomarkers News

> Alzheimer's biomarkers panel not clear-cut after all. News

> Genetic test could up outcomes after lung cancer surgery. Article

> MRS can detect brain tumor biomarker. Item

> NINDS is close to launching its first NeuroNEXT neurobiomarkers study. Story

> Markers from breast could predict weight loss surgery outcome. More

And Finally... A new study says that the norovirus was responsible for 18.2 percent of all infection outbreaks and 65 percent of ward closures in U.S. hospitals during a two-year period. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.